Brief: Hansa Biopharma Announces Positive Topline Data From Imlifidase Phase 2 Study

Hansa Biopharma AB

28/11/2022 17:07

Nov 28 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * HANSA BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM THE
IMLIFIDASE PHASE 2 STUDY IN ANTIBODY MEDIATED REJECTION (AMR)
EPISODES POST KIDNEY TRANSPLANTATION
    * HANSA PLANS TO PUBLISH FULL DATASET FROM STUDY IN 2023
    * TOPLINE DATA ASSOCIATED WITH PRIMARY ENDPOINT SHOWS THAT
IMLIFIDASE HAS SIGNIFICANTLY SUPERIOR EFFICACY
    * HANSA BIOPHARMA - EFFICACY DATA OF DRUG IS SUPERIOR WHEN
COMPARED TO PLASMA EXCHANGE IN REDUCING DSAS DURING 5 DAYS
FOLLOWING START OF TREATMENT

Source text for Eikon:  ID:nWkr3wzLK0 
Further company coverage:  HNSA.ST 
 ((Reuters.briefs@thomsonreuters.com;))